TLSI vs. IRMD, BBNX, CBLL, AVNS, BFLY, KIDS, BVS, RXST, AXGN, and DCTH
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Iradimed (IRMD), Beta Bionics (BBNX), CeriBell (CBLL), Avanos Medical (AVNS), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Bioventus (BVS), RxSight (RXST), AxoGen (AXGN), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.
TriSalus Life Sciences vs.
Iradimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Iradimed received 247 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 65.58% of users gave Iradimed an outperform vote.
Iradimed has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
Iradimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed currently has a consensus target price of $72.00, indicating a potential upside of 35.11%. TriSalus Life Sciences has a consensus target price of $10.93, indicating a potential upside of 103.51%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Iradimed.
92.3% of Iradimed shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 36.8% of Iradimed shares are held by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Iradimed has a net margin of 26.26% compared to TriSalus Life Sciences' net margin of -206.24%. Iradimed's return on equity of 24.12% beat TriSalus Life Sciences' return on equity.
In the previous week, TriSalus Life Sciences had 8 more articles in the media than Iradimed. MarketBeat recorded 10 mentions for TriSalus Life Sciences and 2 mentions for Iradimed. Iradimed's average media sentiment score of 1.83 beat TriSalus Life Sciences' score of 0.00 indicating that Iradimed is being referred to more favorably in the media.
Summary
Iradimed beats TriSalus Life Sciences on 13 of the 19 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:TLSI) was last updated on 5/21/2025 by MarketBeat.com Staff
